October 21, 2019 - Regulatory SynAct conducts private placement and fully guaranteed rights issue with the aim of increasing the commercial value of AP1189
March 29, 2019 - Regulatory SynAct applies for start of phase IIa clinical study in patients with active arthritis
February 11, 2019 - Regulatory SynAct reported positive phase I results for candidate drug AP1189 and prepared funding for broadened phase II programmes
